CoChat
Sign Up
Cited by 16Vibrio bacteria research studiesSalmonella and Campylobacter epidemiologyBacterial Infections and Vaccines

The DOI matches its Crossref record.

Comparative Characterization of Vibrio cholerae O1 from Five Sub-Saharan African Countries Using Various Phenotypic and Genotypic Techniques

Open access
Smith, Anthony M., Njanpop-Lafourcade, Berthe-Marie, Mengel, Martin A., Gessner, Bradford D., Sauvageot, Delphine, Bidjada, Bawimodom, Miwanda, Berthe N., Saliou, Diallo M., N’Douba, Adèle Kacou, Langa, José P., Ismail, Husna, Tau, Nomsa, Sooka, Arvinda, Keddy, Karen. H.·2015·PLOS ONE
DOI 10.1371/journal.pone.0142989PMC PMC4659613
Open this paper in CoChat — free accountOpen PDF

Abstract

We used standardized methodologies to characterize Vibrio cholerae O1 isolates from Guinea, Democratic Republic of the Congo (DRC), Togo, Côte d'Ivoire and Mozambique. We investigated 257 human isolates collected in 2010 to 2013. DRC isolates serotyped O1 Inaba, while isolates from other countries serotyped O1 Ogawa. All isolates were biotype El Tor and positive for cholera toxin. All isolates showed multidrug resistance but lacked ciprofloxacin resistance. Antimicrobial susceptibility profiles of isolates varied between countries. In particular, the susceptibility profile of isolates from Mozambique (East-Africa) included resistance to ceftriaxone and was distinctly different to the susceptibility profiles of isolates from countries located in West- and Central-Africa. Molecular subtyping of isolates using pulsed-field gel electrophoresis (PFGE) analysis showed a complex relationship among isolates. Some PFGE patterns were unique to particular countries and clustered by country; while other PFGE patterns were shared by isolates from multiple countries, indicating that the same genetic lineage is present in multiple countries. Our data add to a better understanding of cholera epidemiology in Africa.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0142989

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The Vibrio cholerae Ogawa biotype has been shown to be the most prevalent in the region, while epidemics are mainly caused by Wave 3 atypical O1 El Tor strain, which has been reported to be resistant to multiple antimicrobials.

    “The V. cholerae Ogawa biotype has been shown to be the most prevalent in the region, while epidemics are mainly caused by Wave 3 atypical O1 El Tor strain, which has been reported to be resistant to multiple antimicrobials”

    From Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? (2022) · cites this paper as [54]

    The Results and Table 1 (pages not available in our copy) show that Ogawa was the serotype in four of the five countries studied and that isolates showed resistance to multiple antimicrobials. The Introduction reports altered El Tor strains in Africa and wave-three El Tor strains in Kenya, but does not establish that epidemics across the region are mainly caused by wave-three atypical El Tor strains. The paper also does not establish that the wave-three strains specifically were multidrug-resistant. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 40

  1. MA Mengel, 2014, Cholera outbreaks in Africa, Curr Top Microbiol Immunol, 379, 117
  2. M Ali, 2012, The global burden of cholera, Bull World Health Organ, 90, 209, 10.2471/BLT.11.093427 · DOI
  3. [Anonymous]World Health Organization (WHO) Weekly Epidemiological Record, 1 August 2014, vol. 89, 31 (pp. 345–356). Cholera 2013. Available at: http://www.who.int/wer/2014/wer8931/en/. Accessed 21 January 2015.
  4. J Kiiru, 2013, A study on the geophylogeny of clinical and environmental Vibrio cholerae in Kenya, PLoS One, 8, e74829, 10.1371/journal.pone.0074829 · DOI
  5. AM Smith, 2008, Characterization of cholera outbreak isolates from Namibia, December 2006 to February 2007, Epidemiol Infect, 136, 1207, 10.1017/S0950268807009685 · DOI
  6. MS Islam, 2011, Phenotypic, genotypic, and antibiotic sensitivity patterns of strains isolated from the cholera epidemic in zimbabwe, J Clin Microbiol, 49, 2325, 10.1128/JCM.00432-11 · DOI
  7. H Ismail, 2013, Cholera outbreak in South Africa, 2008–2009: laboratory analysis of Vibrio cholerae O1 strains, J Infect Dis, 208, S39, 10.1093/infdis/jit200 · DOI
  8. KS Oyedeji, 2013, Molecular characterization of the circulating strains of Vibrio cholerae during 2010 cholera outbreak in Nigeria, J Health Popul Nutr, 31, 178, 10.3329/jhpn.v31i2.16381 · DOI
  9. JF Akoachere, 2013, Multi-drug resistant toxigenic Vibrio cholerae O1 is persistent in water sources in New Bell-Douala, Cameroon, BMC Infect Dis, 13, 366, 10.1186/1471-2334-13-366 · DOI
  10. A Dalsgaard, 2001, Vibrio cholerae O1 outbreak isolates in Mozambique and South Africa in 1998 are multiple-drug resistant, contain the SXT element and the aadA2 gene located on class 1 integrons, J Antimicrob Chemother, 48, 827, 10.1093/jac/48.6.827 · DOI
  11. H Ismail, 2011, Genetic characterization of multidrug-resistant, extended-spectrum- beta-lactamase-producing Vibrio cholerae O1 outbreak strains, Mpumalanga, South Africa, 2008, J Clin Microbiol, 49, 2976, 10.1128/JCM.00293-11 · DOI
  12. B Miwanda, 2015, Antimicrobial Drug Resistance of Vibrio cholerae, Democratic Republic of the Congo, Emerg Infect Dis, 21, 847, 10.3201/eid2105.141233 · DOI
  13. N Pugliese, 2009, SXT-related integrating conjugative element and IncC plasmids in Vibrio cholerae O1 strains in Eastern Africa, J Antimicrob Chemother, 63, 438, 10.1093/jac/dkn542 · DOI
  14. JC Mwansa, 2007, Multiply antibiotic-resistant Vibrio cholerae O1 biotype El Tor strains emerge during cholera outbreaks in Zambia, Epidemiol Infect, 135, 847, 10.1017/S0950268806007254 · DOI
  15. A Dalsgaard, 2000, Class 1 integron-borne, multiple-antibiotic resistance encoded by a 150-kilobase conjugative plasmid in epidemic vibrio cholerae O1 strains isolated in Guinea-Bissau, J Clin Microbiol, 38, 3774, 10.1128/JCM.38.10.3774-3779.2000 · DOI
  16. JA Opintan, 2008, Vibrio cholerae O1 from Accra, Ghana carrying a class 2 integron and the SXT element, J Antimicrob Chemother, 62, 929, 10.1093/jac/dkn334 · DOI
  17. CC Thompson, 2011, Vibrio cholerae O1 lineages driving cholera outbreaks during seventh cholera pandemic in Ghana, Infect Genet Evol, 11, 1951, 10.1016/j.meegid.2011.08.020 · DOI · Paper page
  18. CJ Grim, 2010, Genome sequence of hybrid Vibrio cholerae O1 MJ-1236, B-33, and CIRS101 and comparative genomics with V. cholerae, J Bacteriol, 192, 3524, 10.1128/JB.00040-10 · DOI
  19. M Ansaruzzaman, 2004, Cholera in Mozambique, variant of Vibrio cholerae, Emerg Infect Dis, 10, 2057, 10.3201/eid1011.040682 · DOI
  20. JH Lee, 2006, Multilocus sequence typing (MLST) analysis of Vibrio cholerae O1 El Tor isolates from Mozambique that harbour the classical CTX prophage, J Med Microbiol, 55, 165, 10.1099/jmm.0.46287-0 · DOI
  21. SM Saidi, 2014, Prevalence of Vibrio cholerae O1 El Tor variant in a cholera-endemic zone of Kenya, J Med Microbiol, 63, 415, 10.1099/jmm.0.068999-0 · DOI
  22. NA Bhuiyan, 2012, Genetic characterization of Vibrio cholerae O1 strains isolated in Zambia during 1996–2004 possessing the unique VSP-II region of El Tor variant, Epidemiol Infect, 140, 510, 10.1017/S0950268811000926 · DOI
  23. S Rebaudet, 2014, Deciphering the origin of the 2012 cholera epidemic in Guinea by integrating epidemiological and molecular analyses, PLoS Negl Trop Dis, 8, e2898, 10.1371/journal.pntd.0002898 · DOI
  24. D Talkington, 2011, Characterization of toxigenic Vibrio cholerae from Haiti, 2010–2011, Emerg Infect Dis, 17, 2122, 10.3201/eid1711.110805 · DOI
  25. R De, 2013, The role of Vibrio cholerae genotyping in Africa, J Infect Dis, 208, S32, 10.1093/infdis/jit199 · DOI
  26. AA Mohamed, 2012, Molecular epidemiology of geographically dispersed Vibrio cholerae, Kenya, January 2009-May 2010, Emerg Infect Dis, 18, 925, 10.3201/eid1806.111774 · DOI
  27. AM Smith, 2011, International collaboration tracks typhoid fever cases over two continents from South Africa to Australia, J Med Microbiol, 60, 1405, 10.1099/jmm.0.030700-0 · DOI
  28. O Lunguya, 2012, Salmonella typhi in the democratic republic of the congo: fluoroquinolone decreased susceptibility on the rise, PLoS Negl Trop Dis, 6, e1921, 10.1371/journal.pntd.0001921 · DOI
  29. H Ismail, 2012, Case of imported Vibrio cholerae O1 from India to South Africa, J Infect Dev Ctries, 6, 897, 10.3855/jidc.2448 · DOI
  30. A Mutreja, 2011, Evidence for several waves of global transmission in the seventh cholera pandemic, Nature, 477, 462, 10.1038/nature10392 · DOI
  31. S Rebaudet, 2013, Environmental determinants of cholera outbreaks in inland Africa: a systematic review of main transmission foci and propagation routes, J Infect Dis, 208, S46, 10.1093/infdis/jit195 · DOI
  32. S Rebaudet, 2013, Cholera in coastal Africa: a systematic review of its heterogeneous environmental determinants, J Infect Dis, 208, S98, 10.1093/infdis/jit202 · DOI
  33. LK Ng, 2003, Can Etest be used to determine Vibrio cholerae susceptibility to erythromycin?, Antimicrob Agents Chemother, 47, 1479, 10.1128/AAC.47.4.1479-1480.2003 · DOI
  34. SP Keasler, 1993, Detecting and biotyping Vibrio cholerae O1 with multiplex polymerase chain reaction, Lancet, 341, 1661, 10.1016/0140-6736(93)90792-F · DOI
  35. KA Koskela, 2009, A multiplatform real-time polymerase chain reaction detection assay for Vibrio cholerae, Diagn Microbiol Infect Dis, 65, 339, 10.1016/j.diagmicrobio.2009.07.009 · DOI
  36. KL Cooper, 2006, Development and validation of a PulseNet standardized pulsed-field gel electrophoresis protocol for subtyping of Vibrio cholerae, Foodborne Pathog Dis, 3, 51, 10.1089/fpd.2006.3.51 · DOI
  37. GB Nair, 2002, New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh, J Clin Microbiol, 40, 3296, 10.1128/JCM.40.9.3296-3299.2002 · DOI
  38. MK Waldor, 1996, Lysogenic conversion by a filamentous phage encoding cholera toxin, Science, 272, 1910, 10.1126/science.272.5270.1910 · DOI
  39. JB Kaper, 1995, Cholera, Clin Microbiol Rev, 8, 48, 10.1128/CMR.8.1.48 · DOI
  40. E Folgosa, 2001, Molecular identification of pathogenicity genes and ERIC types in Vibrio cholerae O1 epidemic strains from Mozambique, Epidemiol Infect, 127, 17, 10.1017/S0950268801005623 · DOI

Cited by

Sorted by citations

Metadata

Authors
Smith, A. M., Njanpop-Lafourcade, B.-M., Mengel, M. A., Gessner, B. D., Sauvageot, D., Bidjada, B., Miwanda, B. N., Saliou, D. M., N’Douba, A. K., Langa, J. P., Ismail, H., Tau, N., Sooka, A., & Keddy, K. H.
Affiliations
  • National Health Laboratory Service (ZA)
  • Agence de Médecine Préventive (FR)
  • National Institute of Biomedical Research (CD)
  • Institut National de Santé Publique (GN)
  • Institut Pasteur de Côte d'Ivoire (CI)
  • Instituto Nacional de Saúde (MZ)
Corresponding author
Smith, Anthony M.
ORCID
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2015-11-25
Volume
10
Issue
11
Pages
e0142989
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0142989
PMC
PMC4659613
OpenAlex
W2178493569
Cited by
16
References
0
Citations by year
2025: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 2
FWCI
1.04
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Bill and Melinda Gates Foundation (OPPGH5233)
  • Centers for Disease Control and Prevention (5u19gh000571-02, U19GH000571)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Vibrio bacteria research studies
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
Vibrio cholerae O1, cholera, antimicrobial resistance, multidrug resistance, ceftriaxone resistance, ciprofloxacin resistance, cholera toxin, antimicrobial susceptibility, molecular subtyping, pulsed-field gel electrophoresis, genetic lineages, cholera epidemiology, sub-Saharan Africa, Guinea, Democratic Republic of the Congo, Togo, Côte d'Ivoire, Mozambique
MeSH terms
Adolescent, Adult, Cholera, Female, Genotype, Geography, Humans, Male, Middle Aged, Phenotype, Phylogeny, Population Surveillance, Africa South of the Sahara, Vibrio cholerae O1, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review